We have been instrumental in the discovery of four drugs now on the market
We leverage our accomplishments in drug discovery with our determination to remain at the cutting edge of research to deliver innovation for industry and academia. As your partner, we provide you with robust and cutting edge scientific expertise, honed in global pharma, along with the steadfast support required in a fast-paced and challenging industry.
Science is our cornerstone. Our unprecedented track record in discovering drugs demonstrates this. We capitalize on our shared enthusiasm for innovative R&D, spurred on by our dedication to deliver excellence at every opportunity.
Our expertise spans different modalities including small molecule, peptide and biologic therapeutics. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
Our partners are of the utmost importance. We always strive to go above and beyond your expectations, treating your projects as our highest priority.
We offer a unique blend of broad scientific expertise, global pharma heritage, and unprecedented success in bringing drug discovery projects from conception to the clinic. With a passionate, interdisciplinary and accomplished team, and capabilities ranging from target validation to clinical candidate nomination, we bring great science to your project.
Be sure to visit posters P225 and P277 at the IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2023) in Zagreb, Croatia from 3 – 7 September to learn more about IRBM's exciting #research on novel allosteric SHP2 inhibitors!
IRBM, Rainwater Charitable Foundation (RCF, based in Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) announce the start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. Financial details are not disclosed.
IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD outside the USA and Canada, to continue their collaboration in the peptide therapeutics area.
The Power of NMR in Drug Discovery
Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
Set by Google to distinguish users.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Vimeo installs this cookie to collect tracking information by setting a unique ID to embed videos to the website.